Legislators in the USA have been discussing reforms to reduce the high cost of brand-name drugs, which are much higher in the USA than in other industrialized countries. One solution is to actively negotiate prices based on drugs’ clinical benefits. We discuss two important complexities from such an approach: drugs that have been approved for multiple indications and as part of a combination regimen.

中文翻译：

---

具有多种适应症或组合的药物的基于价值的定价——欧洲的经验教训

美国的立法者一直在讨论改革以降低品牌药的高成本，美国的品牌药成本远高于其他工业化国家。一种解决方案是根据药物的临床效益积极协商价格。我们讨论了这种方法的两个重要复杂性：已被批准用于多种适应症的药物以及作为联合治疗方案的一部分。